Method for screening influenza neutralizing antibodies in crude human plasma and its derivatives using SPR

Khalenkov, Alexey M.; Norton, Malgorzata G.; Scott, Dorothy E.

doi:10.1016/j.heliyon.2023.e15651

Cited by 2 publications

(3 citation statements)

References 31 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One such strategy involved selective use of either α2-3-sialyltransferase or α2-6-sialyltransferase to control the linkage of sialic acid to the subterminal galactose residue (Narla and Sun 2012 ). Alternatively, linkages for which no influenza strains display specificity, like α2-8 attachment, can be produced and used as reference ligands to construct “blank slide” control surfaces (Khalenkov et al 2023 ).…”

Section: Synthetic Glycoconjugatesmentioning

confidence: 99%

Antibody-independent surface plasmon resonance assays for influenza vaccine quality control

Serafin,

Kamen,

de Crescenzo

et al. 2024

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Surface plasmon resonance (SPR)-based biosensors have emerged as a powerful platform for bioprocess monitoring due to their ability to detect biointeractions in real time, without the need for labeling. Paramount for the development of a robust detection platform is the immobilization of a ligand with high specificity and affinity for the in-solution species of interest. Following the 2009 H1N1 pandemic, much effort has been made toward the development of quality control platforms for influenza A vaccine productions, many of which have employed SPR for detection. Due to the rapid antigenic drift of influenza’s principal surface protein, hemagglutinin, antibodies used for immunoassays need to be produced seasonally. The production of these antibodies represents a 6–8-week delay in immunoassay and, thus, vaccine availability. This review focuses on SPR-based assays that do not rely on anti-HA antibodies for the detection, characterization, and quantification of influenza A in bioproductions and biological samples. Key points • The single radial immunodiffusion assay (SRID) has been the gold standard for the quantification of influenza vaccines since 1979. Due to antigenic drift of influenza’s hemagglutinin protein, new antibody reagents for the SRID assay must be produced each year, requiring 6–8 weeks. The resulting delay in immunoassay availability is a major bottleneck in the influenza vaccine pipeline. This review highlights ligand options for the detection and quantification of influenza viruses using surface plasmon resonance biosensors.

show abstract

Section: Synthetic Glycoconjugatesmentioning

confidence: 99%

Antibody-independent surface plasmon resonance assays for influenza vaccine quality control

Serafin,

Kamen,

de Crescenzo

et al. 2024

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

show abstract

“…Thus, the influenza A virus is characterized by high antigenic variability, and based on differences in surface antigens, 11 subtypes conditioned by neuraminidase–NA (N1-N11) and 18 subtypes conditioned by hemagglutinin–HA (H1-H18) are distinguished ( Brydak, 2008 ; Wierzbicka-Woś et al, 2015 ). Pandemic influenza strains arise as a result of antigenic shift and may include avian-derived hemagglutinin (HA) subtypes (such as H5, H7, and H9) or porcine hemagglutinin variants (H1, H2, and H3) which, by acquiring further adaptive mutations, become capable of human-to-human transmission of infection ( Bouvier and Palese, 2008 ; Taubenberger and Kash, 2010 ; Khalenkov et al, 2023 ). Vaccination against influenza is the most effective preventive measure.…”

Section: Introductionmentioning

confidence: 99%

“…However, in order to be effective, it requires constant and thorough worldwide supervision and timely updates of the formulation of the influenza vaccine ( Khalenkov et al, 2023 ). Influenza virus infections, like many other infections, induce an immune response in the infected body, reducing or even cessating virus replication and formation of so-called immunological memory in the patient, protecting against subsequent infection.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of circulating antibodies against hemagglutinin of influenza viruses in epidemic season 2021/2022 in Poland

Kondratiuk,

Hallmann,

Szymański

et al. 2024

Acta Biochim. Pol.

View full text Add to dashboard Cite

The aim of the study was to determine the level of anti-hemagglutinin antibodies in the serum of patients during the 2021/2022 epidemic season in Poland. A total of 700 sera samples were tested, divided according to the age of the patients into 7 age groups: 0–4 years of age, 5–9 years of age, 10–14 years of age, 15–25 years of age, 26–44 years of age, 45–64 years of age and ≥65 years of age, 100 samples were collected from each age group. Anti-hemagglutinin antibody levels was determined using the haemagglutination inhibition assay (OZHA). The results obtained confirm the presence of anti-hemagglutinin antibodies for the antigens A/Victoria/2570/2019 (H1N1) pdm09, A/Cambodia/e0826360/2020 (H3N2), B/Washington/02/2019 and B/Phuket/3073/2013 recommended by World Health Organization (WHO) for the 2021/2022 epidemic season. The analysis of the results shows differences in the levels of individual anti-hemagglutinin antibodies in the considered age groups. In view of very low percentage of the vaccinated population in Poland, which was 6.90% in the 2021/2022 epidemic season, the results obtained in the study would have to be interpreted as the immune system response in patients after a previous influenza virus infection.

show abstract

Method for screening influenza neutralizing antibodies in crude human plasma and its derivatives using SPR

Cited by 2 publications

References 31 publications

Antibody-independent surface plasmon resonance assays for influenza vaccine quality control

Antibody-independent surface plasmon resonance assays for influenza vaccine quality control

Prevalence of circulating antibodies against hemagglutinin of influenza viruses in epidemic season 2021/2022 in Poland

Contact Info

Product

Resources

About